跳至主要内容
临床试验/EUCTR2018-003095-12-BG
EUCTR2018-003095-12-BG进行中(未招募)1 期

An investigator-blinded, active controlled, randomized, twoparallel group, multi-dose clinical trial to prove the non-inferiorefficacy of Lactobacillus plantarum P 17630 100.000.000 CFUsoft vaginal capsules (Proge Farm s.r.l.) versus miconazolenitrate 400 mg vaginal soft capsules in vaginal candidiasis.

PROGE FARM SR0 个研究点目标入组 210 人开始时间: 2019年6月17日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Pre-menopausal women of any race and
  • between 18 to 45 years of age;
  • ? Diagnosis of VVC based on the presence of the
  • following four criteria: pruritus, discharge, pain,
  • ? Negative results on the Bayer evaluating kit
  • (Gyno-Canestest®);
  • ? Negative pregnancy test
  • ? Willing to refrain from using any vaginal product
  • (e.g. spermicide, tampon, douche, diaphragm or
  • condom), other than study product, on study
  • ? Willing to refrain from sexual intercourse on study
  • ? Able to understand the requirements of the
  • clinical trial and to agree to return for the required
  • follow-up visits;
  • ? Willing to provide voluntary written informed
  • consent and data protection declaration before
  • any clinical trail related procedure is performed.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 210
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Menstruating when diagnosis of vulvovaginal
  • candidiasis is determined at Baseline visit;
  • ? Primary or secondary immunodeficiency;
  • ? Severe liver disease;
  • ? History of regional enteritis or ulcerative colitis;
  • ? Current or past evidence of any vulvovaginitis
  • other than bacterial vaginosis (e.g. candidiasis,
  • Trichomonas vaginalis, Chlamydia trachomatis,
  • Neisseria gonorrhoeae, Herpes simplex or
  • human papilloma virus) in the previous 4 months;
  • ? Subject will be under treatment during the study
  • period for cervical intraepithelial neoplasia or
  • cervical carcinoma;
  • ? History of hypersensitivity to miconazole nitrate,
  • Lactobacillus plantarum or any of the
  • components of the formulation;
  • ? Use within 2 weeks prior to baseline of topical or
  • systemic antibiotics/antifungal;
  • ? Use of spermicides, tampons, douches,
  • diaphragms, condoms or other intra-vaginal
  • product within 48 hours prior to dosing on study
  • ? Current participation or not yet completed period
  • of at least 30 days since ending other
  • investigational device or drug trial(s). Use of any
  • experimental medicinal product within the 3
  • months prior to screening.
  • ? Unwillingness or inability to comply with the
  • clinical trial procedures;
  • ? Who are legally incapacitated;
  • ? Who are legally detained in an official institute.

研究者

发起方
PROGE FARM SR

相似试验

进行中(未招募)
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2018-001082-17-ATMENARINI RICERCHE S.p.A.600
进行中(未招募)
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2018-001082-17-HUMENARINI RICERCHE S.p.A.600
进行中(未招募)
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2018-001082-17-CZMENARINI RICERCHE S.p.A.600
进行中(未招募)
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2018-001082-17-ROMENARINI RICERCHE S.p.A.266
进行中(未招募)
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2018-001082-17-HRMENARINI RICERCHE S.p.A.600